WNT secretion and signalling in human disease

Trends in Molecular Medicine

Volumn 18, Issue 8, 2012, Pages 483-493

  Herr, Patrick ^a   Hausmann, George ^a   Basler, Konrad ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; DICKKOPF 1 PROTEIN; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; WNT PROTEIN; WNT1 PROTEIN; WNT10A PROTEIN; WNT10B PROTEIN; WNT11 PROTEIN; WNT2 PROTEIN; WNT3A PROTEIN; WNT4 PROTEIN; WNT5A PROTEIN; WNT5B PROTEIN; WNT6 PROTEIN; WNT7A PROTEIN; WNT7B PROTEIN; WNT8A PROTEIN; WNT8B PROTEIN; WNT9A PROTEIN; WNT9B PROTEIN;

ACYLATION; BIOGENESIS; CELL MEMBRANE; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM; EXTRACELLULAR SPACE; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; HUMANS; NEOPLASMS; PROTEIN TRANSPORT; SECRETORY PATHWAY; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84864395840     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.06.008     Document Type: Review

References (110)

1. Angers S., Moon R.T. Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 2009, 10:468-477.
2. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 2007, 17:45-51.
3. Segalen M., Bellaiche Y. Cell division orientation and planar cell polarity pathways. Semin. Cell Dev. Biol. 2009, 20:972-977.
4. Harterink M., Korswagen H.C. Dissecting the Wnt secretion pathway: key questions on the modification and intracellular trafficking of Wnt proteins. Acta Physiol. (Oxf.) 2012, 204:8-16.
5. Mason J.O., et al. Mutational analysis of mouse Wnt-1 identifies two temperature-sensitive alleles and attributes of Wnt-1 protein essential for transformation of a mammary cell line. Mol. Biol. Cell 1992, 3:521-533.
6. Herr P., Basler K. Porcupine-mediated lipidation is required for Wnt recognition by Wls. Dev. Biol. 2012, 361:392-402.
7. Tang X., et al. Roles of N-glycosylation and lipidation in Wg secretion and signaling. Dev. Biol. 2012, 364:32-41.
8. Ching W., et al. Lipid-independent secretion of a Drosophila Wnt protein. J. Biol. Chem. 2008, 283:17092-17098.
9. Franch-Marro X., et al. In vivo role of lipid adducts on Wingless. J. Cell Sci. 2008, 121:1587-1592.
10. Burrus L.W., McMahon A.P. Biochemical analysis of murine Wnt proteins reveals both shared and distinct properties. Exp. Cell Res. 1995, 220:363-373.
11. Galli L.M., et al. Porcupine-mediated lipid-modification regulates the activity and distribution of Wnt proteins in the chick neural tube. Development 2007, 134:3339-3348.
12. Tanaka K., et al. Misexpression of mouse porcupine isoforms modulates the differentiation of P19 embryonic carcinoma cells. Cell Biol. Int. 2003, 27:549-557.
13. Hofmann K. A superfamily of membrane-bound O-acyltransferases with implications for wnt signaling. Trends Biochem. Sci. 2000, 25:111-112.
14. Galli L.M., Burrus L.W. Differential palmit(e)oylation of Wnt1 on C93 and S224 residues has overlapping and distinct consequences. PLoS ONE 2011, 6:e26636.
15. Barrott J.J., et al. Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12752-12757.
16. Biechele S., et al. Porcupine homolog is required for canonical Wnt signaling and gastrulation in mouse embryos. Dev. Biol. 2011, 355:275-285.
17. Koles K., et al. Mechanism of Evi-exosome release at synaptic boutons. J. Biol. Chem. 2012, 287:16820-16834.
18. Carpenter A.C., et al. Generation of mice with a conditional null allele for Wntless. Genesis 2010, 48:554-558.
19. Fu J., et al. Gpr177/mouse Wntless is essential for Wnt-mediated craniofacial and brain development. Dev. Dyn. 2011, 240:365-371.
20. Coombs G.S., et al. WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. J. Cell Sci. 2010, 123:3357-3367.
21. Port F., Basler K. Wnt trafficking: new insights into Wnt maturation, secretion and spreading. Traffic 2010, 11:1265-1271.
22. Fu J., et al. Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18598-18603.
23. Cullen P.J., Korswagen H.C. Sorting nexins provide diversity for retromer-dependent trafficking events. Nat. Cell Biol. 2011, 14:29-37.
24. Gasnereau I., et al. Identification of an endocytosis motif in an intracellular loop of Wntless protein, essential for its recycling and the control of Wnt protein signaling. J. Biol. Chem. 2011, 286:43324-43333.
25. Schwarz D.G., et al. Genetic analysis of sorting nexins 1 and 2 reveals a redundant and essential function in mice. Mol. Biol. Cell 2002, 13:3588-3600.
26. Lee J.J., et al. Identification and characterization of a novel, evolutionarily conserved gene disrupted by the murine H beta 58 embryonic lethal transgene insertion. Development 1992, 115:277-288.
27. Harterink M., et al. A SNX3-dependent retromer pathway mediates retrograde transport of the Wnt sorting receptor Wntless and is required for Wnt secretion. Nat. Cell Biol. 2011, 13:914-923.
28. Zhang P., et al. SNX3 controls Wingless/Wnt secretion through regulating retromer-dependent recycling of Wntless. Cell Res. 2011, 21:1677-1690.
29. Panakova D., et al. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 2005, 435:58-65.
30. Neumann S., et al. Mammalian Wnt3a is released on lipoprotein particles. Traffic 2009, 10:334-343.
31. Mulligan K.A., et al. Secreted Wingless-interacting molecule (Swim) promotes long-range signaling by maintaining Wingless solubility. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:370-377.
32. Katanaev V.L., et al. Reggie-1/flotillin-2 promotes secretion of the long-range signalling forms of Wingless and Hedgehog in Drosophila. EMBO J. 2008, 27:509-521.
33. Yan D., Lin X. Shaping morphogen gradients by proteoglycans. Cold Spring Harb. Perspect. Biol. 2009, 1:a002493.
34. Mii Y., Taira M. Secreted Wnt 'inhibitors' are not just inhibitors: regulation of extracellular Wnt by secreted Frizzled-related proteins. Dev. Growth Differ. 2011, 53:911-923.
35. Bovolenta P., et al. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J. Cell Sci. 2008, 121:737-746.
36. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25:7469-7481.
37. Semenov M., et al. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 2005, 280:26770-26775.
38. Lintern K.B., et al. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 2009, 284:23159-23168.
39. de Lau W., et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011, 476:293-297.
40. van Amerongen R., et al. Alternative wnt signaling is initiated by distinct receptors. Sci. Signal. 2008, 1:re9.
41. van Amerongen R., Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136:3205-3214.
42. Mazieres J., et al. Wnt signaling in lung cancer. Cancer Lett. 2005, 222:1-10.
43. Pulkkinen K., et al. Wnt signaling in kidney development and disease. Organogenesis 2008, 4:55-59.
44. Hughes K.R., et al. Expression profiling of Wnt family of genes in normal and inflammatory bowel disease primary human intestinal myofibroblasts and normal human colonic crypt epithelial cells. Inflamm. Bowel Dis. 2011, 17:213-220.
45. Gersemann M., et al. From intestinal stem cells to inflammatory bowel diseases. World J. Gastroenterol. 2011, 17:3198-3203.
46. Liu X., et al. Wnt2 inhibits enteric bacterial-induced inflammation in intestinal epithelial cells. Inflamm. Bowel Dis. 2012, 18:418-429.
47. Kanazawa A., et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am. J. Hum. Genet. 2004, 75:832-843.
48. Khosla S., et al. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 2008, 118:421-428.
49. Bafico A., et al. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004, 6:497-506.
50. Akiri G., et al. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 2009, 28:2163-2172.
51. van't Veer L.J., et al. Molecular cloning and chromosomal assignment of the human homolog of int-1, a mouse gene implicated in mammary tumorigenesis. Mol. Cell. Biol. 1984, 4:2532-2534.
52. Tekmal R.R., Keshava N. Role of MMTV integration locus cellular genes in breast cancer. Front. Biosci. 1997, 2:d519-d526.
53. Zeng Y.A., Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010, 6:568-577.
54. Huguet E.L., et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 1994, 54:2615-2621.
55. Zhang H., et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-Catenin pathway. Cancer Lett. 2012, 323:106-113.
56. Scheel C., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
57. Grzeschik K.H., et al. Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat. Genet. 2007, 39:833-835.
58. Wang X., et al. Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat. Genet. 2007, 39:836-838.
59. Augustin I., et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol. Med. 2012, 4:38-51.
60. Muhammad A., et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7327-7332.
61. Vilarino-Guell C., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 2011, 89:162-167.
62. Taketo M.M. Shutting down Wnt signal-activated cancer. Nat. Genet. 2004, 36:320-322.
63. Kongkham P.N., et al. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 2010, 29:3017-3024.
64. Schlange T., et al. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007, 9:R63.
65. Papapoulos S.E. Targeting sclerostin as potential treatment of osteoporosis. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i119-i122.
66. Menezes M.E., et al. Dickkopf1: a tumor suppressor or metastasis promoter?. Int. J. Cancer 2012, 130:1477-1483.
67. Van Scoyk M., et al. Wnt signaling pathway and lung disease. Transl. Res. 2008, 151:175-180.
68. He B., et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004, 6:7-14.
69. He B., et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005, 24:3054-3058.
70. Lavergne E., et al. Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active beta-catenin. Oncogene 2011, 30:423-433.
71. Chen B., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009, 5:100-107.
72. Jin J., et al. Interaction of the μ-opioid receptor with GPR177 (Wntless) inhibits Wnt secretion: potential implications for opioid dependence. BMC Neurosci. 2010, 11:33.
73. Rosso S.B., et al. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat. Neurosci. 2005, 8:34-42.
74. Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 2008, 275:2677-2683.
75. Li S., et al. Dickkopf-1 is involved in invasive growth of esophageal cancer cells. J. Mol. Histol. 2011, 42:491-498.
76. Kuhnert F., et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:266-271.
77. Gonzalez-Sancho J.M., et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer. Oncogene 2005, 24:1098-1103.
78. Eldar-Finkelman H., et al. Substrate competitive GSK-3 inhibitors - strategy and implications. Biochim. Biophys. Acta 2010, 1804:598-603.
79. Taelman V.F., et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 2010, 143:1136-1148.
80. Mosimann C., et al. β-Catenin hits chromatin: regulation of Wnt target gene activation. Nat. Rev. Mol. Cell Biol. 2009, 10:276-286.
81. Metcalfe C., Bienz M. Inhibition of GSK3 by Wnt signaling - two contrasting models. J. Cell Sci. 2011, 124:3537-3544.
82. Wexler E.M., et al. Genome-wide analysis of a wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci. Signal. 2011, 4:ra65.
83. Fu L., et al. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/β-catenin signalling pathway. Gut 2011, 60:1635-1643.
84. Dolmans G.H., et al. Wnt signaling and Dupuytren's disease. N. Engl. J. Med. 2011, 365:307-317.
85. You J., et al. Wnt pathway-related gene expression in inflammatory bowel disease. Dig. Dis. Sci. 2008, 53:1013-1019.
86. Niemann S., et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am. J. Hum. Genet. 2004, 74:558-563.
87. Liu X., et al. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med. Genet. 2011, 12:104.
88. Chiquet B.T., et al. Variation in WNT genes is associated with non-syndromic cleft lip with or without cleft palate. Hum. Mol. Genet. 2008, 17:2212-2218.
89. Biason-Lauber A., et al. A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46, XX woman. N. Engl. J. Med. 2004, 351:792-798.
90. Li B., et al. WNT5A signaling contributes to Aβ-induced neuroinflammation and neurotoxicity. PLoS ONE 2011, 6:e22920.
91. Bitler B.G., et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011, 71:6184-6194.
92. Levanen B., et al. Increased pulmonary Wnt (wingless/integrated)-signaling in patients with sarcoidosis. Respir. Med. 2011, 105:282-291.
93. Salpea K.D., et al. The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjects. Nutr. Metab. Cardiovasc. Dis. 2009, 19:140-145.
94. Beaty T.H., et al. Analysis of candidate genes on chromosome 2 in oral cleft case-parent trios from three populations. Hum. Genet. 2006, 120:501-518.
95. Woods C.G., et al. Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome. Am. J. Hum. Genet. 2006, 79:402-408.
96. Garavelli L., et al. Al-Awadi-Raas-Rothschild (limb/pelvis/uterus-hypoplasia/aplasia) syndrome and WNT7A mutations: genetic homogeneity and nosological delineation. Am. J. Med. Genet. A 2011, 155A:332-336.
97. Ni M., et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011, 20:119-131.
98. Adaimy L., et al. Mutation in WNT10A is associated with an autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal dysplasia. Am. J. Hum. Genet. 2007, 81:821-828.
99. Christodoulides C., et al. WNT10B mutations in human obesity. Diabetologia 2006, 49:678-684.
100. Liu X., et al. Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G992-G1003.
101. Blom A.B., et al. To seek shelter from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis therapy. Curr. Drug Targets 2010, 11:620-629.
102. Gong Y., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
103. Little R.D., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 2002, 70:11-19.
104. Bjorklund P., et al. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS ONE 2009, 4:e4243.
105. Mani A., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
106. Hsu Y.H., et al. An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility loci for osteoporosis-related traits. PLoS Genet. 2010, 6:e1000977.
107. Zimprich A., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011, 89:168-175.
108. Wu P., et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin. Cancer Res. 2011, 17:6347-6355.
109. Lin Y.W., et al. Methylation analysis of SFRP genes family in cervical adenocarcinoma. J. Cancer Res. Clin. Oncol. 2009, 135:1665-1674.
110. Ekstrom E.J., et al. Methylation and loss of secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion. PLoS ONE 2011, 6:e18674.